Sign in

    Shaymus Contorno

    Research Analyst at Oppenheimer & Co. Inc.

    Shaymus Contorno is an Equity Research Analyst specializing in the MedTech sector at Oppenheimer & Co. Inc., where he focuses on healthcare technology and related industries. He covers companies including TriSalus Life Sciences Inc, Varex Imaging Corporation, and STRATA Skin Sciences, actively participating in earnings calls and industry events. Contorno began his finance career after earning a graduate degree from Stony Brook University, and has been with Oppenheimer since at least 2023, holding both investment adviser and broker registrations. He holds the FINRA Series 63 license and is registered to provide investment advice through Oppenheimer & Co. Inc.

    Shaymus Contorno's questions to TriSalus Life Sciences (TLSI) leadership

    Shaymus Contorno's questions to TriSalus Life Sciences (TLSI) leadership • Q2 2025

    Question

    Shaymus Contorno from Oppenheimer & Co. Inc. asked how the new mapping code has specifically changed TriNav usage patterns and inquired about the timeline and ideal partner profile for the nalotolimod program.

    Answer

    CEO Mary Szela explained that while it's too early for definitive claims data, rep-reported information shows a 'big acceleration' in mapping usage since May, supported by educational webinars from a reimbursement consultant. Regarding nalotolimod, Szela stated final data will be ready in Q3 to begin partnership discussions, with the ideal partner being one focused on liver and pancreas cancer that understands the TLR9 mechanism.

    Ask Fintool Equity Research AI

    Shaymus Contorno's questions to Varex Imaging (VREX) leadership

    Shaymus Contorno's questions to Varex Imaging (VREX) leadership • Q3 2025

    Question

    Shaymus Contorno from Oppenheimer & Co. Inc. inquired about the sustainability of the capital spending environment into fiscal 2026, the specific modalities driving strength in the Medical segment, and requested more concrete timelines for photon counting commercialization.

    Answer

    CFO Shubham Maheshwari characterized the demand environment as healthy and expects a decent start to fiscal 2026, noting that the inventory destocking from fiscal 2024 is over. He identified CT and the Industrial segment as key areas of strength. CEO Sunny Sanyal and Maheshwari reiterated the $150 million revenue target for photon counting by 2029 and confirmed they are now actively engaged with two major medical OEMs on system design and integration.

    Ask Fintool Equity Research AI

    Shaymus Contorno's questions to Varex Imaging (VREX) leadership • Q2 2025

    Question

    Shaymus Contorno of Oppenheimer asked for an update on the India plant and whether its development could be accelerated to mitigate tariff impacts. He also inquired about the current business environment, specifically if Varex is passing on tariff-related costs to customers and if there has been any pushback.

    Answer

    CEO Sunny Sanyal confirmed the India project is on schedule and the company is exploring accelerating certain aspects to help with tariff mitigation, including qualifying local suppliers. CFO Sam Maheshwari stated that the strategy is to pass tariff costs to customers without a markup. He noted that Varex has already begun this process and is in active discussions with its large customers.

    Ask Fintool Equity Research AI

    Shaymus Contorno's questions to LEMAITRE VASCULAR (LMAT) leadership

    Shaymus Contorno's questions to LEMAITRE VASCULAR (LMAT) leadership • Q1 2025

    Question

    Shaymus Contorno questioned the confidence behind the significant full-year guidance increase, given factors like the Artegraft approval and the Aleutia agreement cessation. He also sought an update on the M&A pipeline and clarification on the 'strategic optionality' provided by the company's cash balance.

    Answer

    CEO George LeMaitre attributed the confidence to several factors: a strong Q1 beat, better-than-expected price increases, increased sales rep hiring targets, and the new Artegraft CE Mark approval. He clarified that the 'strategic optionality' comment was not a hint at a specific deal. President Dave Roberts added that the M&A pipeline is strong, focusing on open vascular surgery and adjacent cardiac surgery, with a sweet spot for targets with revenues of $15 million to $150 million.

    Ask Fintool Equity Research AI